Drugs / CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05625594 | Jun 2023 → May 2028 expected | central nervous system non-hodgkin lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05625594 ↗ |
| Modality | Cell therapy | “CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.” NCT05625594 ↗ |
| Route | Other | “Given ICV” NCT05625594 ↗ |
| Target | CD19 | “Then the gene for a special receptor that binds to a certain protein, CD19, on the patient's cancer cells is added to the T cells in the laboratory.” NCT05625594 ↗ |